Project Grant R01CA304343
Award Date 8/11/25
Completion Date 7/31/30
Dollars Obligated $690K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $305,031 Project Grant to Round Table Research, Inc. under the Cancer Treatment Research program (CFDA 93.395) to advance extracellular vesicle (EV) therapy for the treatment of glioblastoma (GBM), an aggressive form of brain cancer. The funded project, conducted in collaboration with researchers at the University of North Carolina-Chapel Hill, seeks to develop engineered tumoricidal EVs derived from induced neural stem cells (iNSCs) as a promising...
- This $531,550 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting research to discover novel druggable oncogenes that block neuroblastoma (NBL) cell differentiation and evaluate inhibitors of those oncogenes as potential differentiation therapy agents. The project aims to systematically screen the human druggable genome using a high-content siRNA screening approach to identify key oncogenes that prevent NBL cell...
- The National Cancer Institute (NCI) awarded a Project Grant under CFDA 93.395 - Cancer Treatment Research to St. Jude Children's Research Hospital Inc. for $768,713 on August 1, 2025. The funding supports research to dissect how the EP300 and CBP histone acetyltransferase proteins control cell state-specific phenotypes and chemosensitivity in high-risk neuroblastoma. The objectives are to capitalize on transcriptional control to identify mechanism-based, targeted cancer therapies that can...
- This Project Grant award of $562,869, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to define the role of chromosome 17q gain in the malignancy of neuroblastoma, the most common pediatric extracranial solid tumor. The principal investigators at Children's Hospital Los Angeles will use a human stem cell model of neuroblastoma to: 1) compare the tumorigenic potential of 17q gain and MYCN in immature cells...
- This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...
- The National Cancer Institute awarded a $148,500 Project Grant under the Cancer Biology Research Program (CFDA 93.396) to the University of North Texas to evaluate the role of extracellular vesicles in modulating the tumor microenvironment, with a focus on their impact on T cell infiltration and suppression in non-small cell lung cancer (NSCLC) and prostate cancer. The project aims to identify specific subpopulations of tumor-derived extracellular vesicles, such as TGN46+ vesicles, that...
- This $131,300 federal Project Grant was awarded on July 15, 2025 by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to Middle Tennessee State University (MTSU). The grant supports the development of a novel dual inhibitor for the treatment of MYCN-amplified neuroblastoma, the most common extracranial cancer in children. The project aims to leverage two key MYCN cofactors, WDR5 and G9A, as targets for small molecule inhibition to disrupt the oncogenic...
- The Department of the Army Medical Command awarded a $2,247,531 project grant to The Children's Hospital of Philadelphia through the Military Medical Research and Development program (CFDA 12.420) to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. The four-year project beginning September 1, 2022 will apply basic, applied, and advanced biomedical research approaches to transform pediatric cancer care and investigate...
- The U.S. National Cancer Institute (NCI) has awarded a $3,480,276 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The funding will support a 4-year research initiative to systematically uncover the genomic heterogeneity of pediatric and adolescent/young adult Philadelphia chromosome-positive (Ph+) and ABL-class Ph-like acute lymphoblastic leukemia (ALL). The overarching goals are to...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $559,030 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Medical University of South Carolina. The grant supports a 5-year research project to "Uncover the Signaling Mechanisms Underlying Treatment Failure in Medulloblastoma". The objective is to investigate the signaling pathways that enable certain progenitor cell populations to...